LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Cerrado

SectorSanidad

8.28 -0.24

Resumen

Variación precio

24h

Actual

Mínimo

8.27

Máximo

8.46

Métricas clave

By Trading Economics

Ingresos

5.1M

5.1M

Ventas

18M

163M

Margen de beneficios

3.113

Empleados

580

EBITDA

-84M

-62M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+110.59% upside

Dividendos

By Dow Jones

Próximas Ganancias

3 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-88M

1.7B

Apertura anterior

8.52

Cierre anterior

8.28

Noticias sobre sentimiento de mercado

By Acuity

32%

68%

94 / 371 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 sept 2025, 23:07 UTC

Adquisiciones, fusiones, absorciones

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2 sept 2025, 22:10 UTC

Principales Movimientos del Mercado

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2 sept 2025, 21:47 UTC

Ganancias

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2 sept 2025, 16:52 UTC

Principales Movimientos del Mercado

CleanCore Solutions Shares Drop After $175 Million Private Investment

2 sept 2025, 22:47 UTC

Charlas de Mercado

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2 sept 2025, 21:40 UTC

Adquisiciones, fusiones, absorciones

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2 sept 2025, 21:07 UTC

Ganancias

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2 sept 2025, 21:07 UTC

Ganancias

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2 sept 2025, 21:05 UTC

Ganancias

Couche-Tard 1Q Rev $17.35B >ATD.T

2 sept 2025, 21:05 UTC

Ganancias

Couche-Tard 1Q Adj EPS 78c >ATD.T

2 sept 2025, 21:05 UTC

Ganancias

Couche-Tard 1Q EPS 82c >ATD.T

2 sept 2025, 21:05 UTC

Ganancias

Couche-Tard 1Q Net $782.5M >ATD.T

2 sept 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

2 sept 2025, 20:53 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2 sept 2025, 20:51 UTC

Adquisiciones, fusiones, absorciones

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 sept 2025, 20:27 UTC

Ganancias

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2 sept 2025, 20:24 UTC

Adquisiciones, fusiones, absorciones

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2 sept 2025, 20:18 UTC

Adquisiciones, fusiones, absorciones

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2 sept 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2 sept 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2 sept 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2 sept 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2 sept 2025, 19:55 UTC

Ganancias

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2 sept 2025, 19:50 UTC

Adquisiciones, fusiones, absorciones

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2 sept 2025, 19:09 UTC

Charlas de Mercado

Oil Futures Gain on Geopolitical Premium -- Market Talk

2 sept 2025, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2 sept 2025, 18:12 UTC

Charlas de Mercado

Gold Pushes To New Record -- Market Talk

2 sept 2025, 17:04 UTC

Charlas de Mercado

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2 sept 2025, 16:57 UTC

Adquisiciones, fusiones, absorciones

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

110.59% repunte

Estimación a 12 Meses

Media 17.5 USD  110.59%

Máximo 30 USD

Mínimo 12 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

94 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.